Drug Profile
Research programme: anticancer antibodies - Bayer Schering Pharma/Vaccinex
Alternative Names: VX 50Latest Information Update: 01 Jun 2010
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma; Vaccinex
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
- 10 Feb 2006 Preclinical trials in Cancer in USA (unspecified route)